1-11 of 11
Daisuke Honma
Close
Sort by
Journal Articles

PRC2-Mediated Apoptosis Evasion Is a Therapeutic Target of MDS/AML Harboring Inv(3)/t(3;3) and -7

Hiroyoshi Kunimoto, Ayaka Miura, Maiko Sagisaka, Mieko Ito, Daisuke Honma, Shinji Tsutsumi, Takayuki Sakuma, Takuma Ohashi, Hiroshi Teranaka, Junji Ikeda, Takashi Toya, Yuka Harada, Noriko Doki, Sheng F. Cai, Akihide Yoshimi, Hiroaki Goto, Ross L Levine, Hideaki Nakajima
Journal: Blood
Blood (2023) 142 (Supplement 1): 2803.
https://doi.org/10.1182/blood-2023-178436
Published: 2023
Journal Articles

Targeting EZH1/2 to Restore Chemosensitivity in Dormant Myeloid Leukemia Stem Cells

Kyung Hee Chang, Mahesh Basyal, Zoe Alaniz, Daisuke Honma, Shinji Tsutsumi, Cedric E. Dos Santos, Naval Daver, Michael Andreeff
Journal: Blood
Blood (2021) 138 (Supplement 1): 2943.
https://doi.org/10.1182/blood-2021-152884
Published: 2021
Journal Articles

EZH1/2 Dual Inhibitor Valemetostat Tosylate (DS-3201b) Acts Differently from EZH2 Selective Inhibitor on Epigenetic Landscape to Exert Greater Anti-Tumor Effect Against Diffuse Large B-Cell Lymphoma

Toshihiro Banjo, Yasuhiro Hama, Emi Nosaka, Yoshimi Takata, Daisuke Honma, Mayumi Kitagawa, Yuka Yamamoto, Chisa Wada, Takanori Yoshida, Kyungtaek Lim, Atsushi Okamoto, Erina Sato, Yumiko Katayama, Kazumi Sato, Hiroki Goto, Yuki Abe
Journal: Blood
Blood (2021) 138 (Supplement 1): 2948.
https://doi.org/10.1182/blood-2021-146772
Published: 2021
Journal Articles

Anti-Tumor Effect of the EZH1/2 Dual Inhibitor Valemetostat Against Diffuse Large B-Cell Lymphoma Via Modulation of B-Cell Receptor Signaling and c-Myc Signaling Pathways

Yasuhiro Hama, PhD, Toshihiro Banjo, PhD, Daisuke Honma, PhD, Yoshimi Takata, Emi Nosaka, Machiko Shiroishi, Kenji Watanabe, Yuka Yamamoto, Tsuyoshi Hirata, Rika Nakano, Koichiro Inaki, PhD, Hiroki Goto, PhD, Yusuke Totoki, PhD, Miki Kataoka, Kyungtaek Lim, PhD, Chisa Wada, Eiji Kumazawa, PhD, Shinji Tsutsumi, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4642.
https://doi.org/10.1182/blood-2019-125436
Published: 2019
Journal Articles

DS-3201, a Potent EZH1/2 Dual Inhibitor, Demonstrates Antitumor Activity Against Non-Hodgkin Lymphoma (NHL) Regardless of EZH2 Mutation

Daisuke Honma, PhD, Emi Nosaka, Machiko Shiroishi, Yoshimi Takata, Yasuhiro Hama, Yuka Yamamoto, Nobuaki Adachi, PhD, Dai Maruyama, MD PhD, Kensei Tobinai, MD PhD, Takashi Ishida, MD PhD, Shigeru Kusumoto, MD, Kenji Ishitsuka, MD PhD, Yoshitaka Imaizumi, MD, PhD, Shogo Takeuchi, MD, Kunihiro Tsukasaki, MD PhD, Tomoyuki Fujioka, Jun Watanabe, Osamu Kanno, PhD, Eiji Kumazawa, PhD, Sumiaki Fujitani, MSc, Kazushi Araki, DVM, PhD, Kosaku Fujiwara, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2217.
https://doi.org/10.1182/blood-2018-99-113379
Published: 2018
Journal Articles

Development and Characterization of the Novel Orally Bioavailable EZH1/2 Dual Inhibitor DS-3201

Daisuke Honma, PhD, Nobuaki Adachi, PhD, Osamu Kanno, PhD, Jun Watanabe, Makoto Hirasawa, Emi Nosaka, Machiko Shiroishi, Takeshi Takizawa, Isao Yasumatsu, Takao Horiuchi, PhD, Akira Nakao, PhD, Keisuke Suzuki, Tomonori Yamasaki, Katsuyoshi Nakajima, Miho Hayakawa, Takanori Yamazaki, Kazushi Araki, D.V.M., PhD, Kosaku Fujiwara, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2073.
https://doi.org/10.1182/blood.V130.Suppl_1.2073.2073
Published: 2017
Journal Articles

Novel Stem Cell-Targeted Therapy for Multiple Myeloma Based on Dual Inhibition of EZH1/2

Makoto Nakagawa, MD, Shuhei Fujita, MD BS, Daisuke Honma, PhD, Kazushi Araki, D.V.M., PhD, Tatsuya Inoue, Ayako Kato, Koichiro Inaki, PhD, Chisa Wada, Ono Yoshimasa, Yasuharu Nakashima, MDPhD, Issay Kitabayashi, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 590.
https://doi.org/10.1182/blood.V130.Suppl_1.590.590
Published: 2017
Journal Articles

EZH1/2, SWI/SNF, and MLL2 Dependent Heterochromatin Formation and Abnormal Transcriptome in Hematological Malignancies

Makoto Yamagishi, PhD, Dai Fujikawa, PhD, Makoto Hori, Daisuke Honma, PhD, Nobuaki Adachi, PhD, Seiichiro Kobayashi, MD, PhD, Masako Iwanaga, MD PhD MPH, Atae Utsunomiya, MD, Seiji Okada, MD, PhD, Kunihiro Tsukasaki, MD PhD, Kensei Tobinai, MD PhD, Kazushi Araki, D.V.M., PhD, Toshiki Watanabe, MD, PhD, Kaoru Uchimaru, MD, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1200.
https://doi.org/10.1182/blood.V130.Suppl_1.1200.1200
Published: 2017
Journal Articles

Development and Molecular Analysis of Synthetic Lethality By Targeting EZH1 and EZH2 in Non-Hodgkin Lymphomas

Makoto Yamagishi, PhD, Makoto Hori, Dai Fujikawa, PhD, Daisuke Honma, PhD, Nobuaki Adachi, PhD, Takeo Ohsugi, D.V.M., PhD, Kazumi Nakano, PhD, Makoto Nakashima, Seiichiro Kobayashi, MD, PhD, Masako Iwanaga, MD, PhD, Atae Utsunomiya, MD, PhD, Seiji Okada, MD, PhD, Kunihiro Tsukasaki, MD, Kensei Tobinai, MD, PhD, Kazushi Araki, D.V.M., PhD, Toshiki Watanabe, MD, PhD, Kaoru Uchimaru, MD PhD
Journal: Blood
Blood (2016) 128 (22): 462.
https://doi.org/10.1182/blood.V128.22.462.462
Published: 2016
Journal Articles

Novel Leukemia Stem Cell-Targeted Therapy for Acute Myeloid Leukemia Based on Dual Inhibition of Ezh1/Ezh2

Shuhei Fujita, MD BS, Daisuke Honma, PhD, Nobuaki Adachi, PhD, Kazushi Araki, D.V.M., PhD, Emi Takamatsu, PhD, Kazumasa Aoyama, PhD, Atsushi Iwama, MD PhD, Issay Kitabayashi, PhD
Journal: Blood
Blood (2015) 126 (23): 457.
https://doi.org/10.1182/blood.V126.23.457.457
Published: 2015
Journal Articles

Polycomb-Dependent Epigenetic Landscape in Adult T Cell Leukemia (ATL); Providing Proof of Concept for Targeting EZH1/2 to Selectively Eliminate the HTLV-1 Infected Population

Makoto Yamagishi, PhD, Dai Fujikawa, Daisuke Honma, PhD, Nobuaki Adachi, PhD, Shota Nakagawa, Makoto Hori, Naoya Kurokawa, Ai Soejima, Kazumi Nakano, PhD, Tadanori Yamochi, PhD, Makoto Nakashima, Seiichiro Kobayashi, MD, PhD, Yuetsu Tanaka, MD, PhD, Masako Iwanaga, MD, PhD, Atae Utsunomiya, MD, PhD, Kaoru Uchimaru, MD, PhD, Kunihiro Tsukasaki, MD, PhD, Kazushi Araki, D.V.M., PhD, Toshiki Watanabe, MD, PhD
Journal: Blood
Blood (2015) 126 (23): 572.
https://doi.org/10.1182/blood.V126.23.572.572
Published: 2015